467 related articles for article (PubMed ID: 18537979)
41. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab.
Grange F; Maubec E; Bagot M; Beylot-Barry M; Joly P; Dalle S; Delaporte E; Dereure O; Bachelez H; Vergier B; Petrella T; D'Incan M
Arch Dermatol; 2009 Mar; 145(3):329-30. PubMed ID: 19289772
[No Abstract] [Full Text] [Related]
42. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence.
Burkhardt B; Zimmermann M; Oschlies I; Niggli F; Mann G; Parwaresch R; Riehm H; Schrappe M; Reiter A;
Br J Haematol; 2005 Oct; 131(1):39-49. PubMed ID: 16173961
[TBL] [Abstract][Full Text] [Related]
43. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
[TBL] [Abstract][Full Text] [Related]
44. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.
Shipp MA; Ross KN; Tamayo P; Weng AP; Kutok JL; Aguiar RC; Gaasenbeek M; Angelo M; Reich M; Pinkus GS; Ray TS; Koval MA; Last KW; Norton A; Lister TA; Mesirov J; Neuberg DS; Lander ES; Aster JC; Golub TR
Nat Med; 2002 Jan; 8(1):68-74. PubMed ID: 11786909
[TBL] [Abstract][Full Text] [Related]
45. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
Gundrum JD; Mathiason MA; Moore DB; Go RS
J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
[TBL] [Abstract][Full Text] [Related]
46. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
Park YH; Sohn SK; Kim JG; Lee MH; Song HS; Kim MK; Jung JS; Lee JJ; Kim HJ; Kim DH
Clin Cancer Res; 2009 Mar; 15(6):2107-15. PubMed ID: 19276283
[TBL] [Abstract][Full Text] [Related]
47. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
Lai GG; Lim ST; Tao M; Chan A; Li H; Quek R
Am J Hematol; 2009 Jul; 84(7):414-7. PubMed ID: 19415727
[TBL] [Abstract][Full Text] [Related]
48. Diffuse large B-cell lymphomas and burkitt lymphoma.
de Leval L; Hasserjian RP
Hematol Oncol Clin North Am; 2009 Aug; 23(4):791-827. PubMed ID: 19577170
[TBL] [Abstract][Full Text] [Related]
49. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
Frick M; Dörken B; Lenz G
Best Pract Res Clin Haematol; 2012 Mar; 25(1):3-12. PubMed ID: 22409819
[TBL] [Abstract][Full Text] [Related]
50. Non-Hodgkin's lymphoma (diffuse large B cell lymphoma).
Copson E
Clin Evid; 2005 Jun; (13):1-18. PubMed ID: 16135258
[No Abstract] [Full Text] [Related]
51. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation.
Sevilla DW; Gong JZ; Goodman BK; Buckley PJ; Rosoff P; Gockerman JP; Lagoo AS
Am J Clin Pathol; 2007 Dec; 128(6):981-91. PubMed ID: 18024324
[TBL] [Abstract][Full Text] [Related]
52. Therapy of diffuse large B-cell lymphomas.
Pfreundschuh M
Eur J Cancer; 2009 Sep; 45 Suppl 1():386-7. PubMed ID: 19775641
[No Abstract] [Full Text] [Related]
53. [Standard or up-to-date treatment for high risk, relapsed and refractory DLBCL].
Kagami Y
Rinsho Ketsueki; 2010 Oct; 51(10):1409-16. PubMed ID: 20962474
[No Abstract] [Full Text] [Related]
54. HIV-related lymphoma treated with maintenance thalidomide.
Larson ML; Enschede SH; Gregory SA
Clin Adv Hematol Oncol; 2005 Mar; 3(3):231-4; discussion 234-5. PubMed ID: 16166993
[No Abstract] [Full Text] [Related]
55. [Treatment approaches for diffuse large B-cell lymphoma].
Miyazaki K; Yamaguchi M
Nihon Rinsho; 2014 Mar; 72(3):483-7. PubMed ID: 24724408
[TBL] [Abstract][Full Text] [Related]
56. Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication.
Ghesquières H; Ferlay C; Sebban C; Chassagne C; Carausu L; Gargi T; Favier B; Philip I; Blay JY; Biron P
Hematol Oncol; 2008 Sep; 26(3):139-47. PubMed ID: 18383186
[TBL] [Abstract][Full Text] [Related]
57. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
58. Large B-cell non-Hodgkin's lymphoma presenting as a laryngeal cyst.
Agada FO; Mistry D; Grace AR; Coatesworth AP
J Laryngol Otol; 2005 Aug; 119(8):658-60. PubMed ID: 16102228
[TBL] [Abstract][Full Text] [Related]
59. A male with primary breast lymphoma.
Miura Y; Nishizawa M; Kaneko H; Watanabe M; Tsudo M
Am J Hematol; 2009 Mar; 84(3):191-2. PubMed ID: 18932237
[No Abstract] [Full Text] [Related]
60. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
